BRIDGEWATER, NJ — Bausch + Lomb, a leading global eye health company, will present a wide array of scientific posters during the Association for Research in Vision and Ophthalmology (ARVO) Annual meeting in Orlando, Fla. (May 4-8). The presentations will address the outcomes of research studies from the company’s current product offerings and pipeline programs in Pharmaceuticals, contact lenses and lens care, in addition to other subjects of interest.
“Bausch + Lomb is dedicated to exploring new solutions and treatment options for eye health, including insights into macular degeneration and innovative ways to treat ocular inflammation that improve upon the current standard of care,” said Cal Roberts, MD, Chief Medical Officer, Bausch + Lomb. “Year after year, ARVO provides the ideal forum in which to share our latest research with the eye care community and help to refine and advance how eye care professionals meet the evolving needs of their patients.”
The research supported by Bausch + Lomb covers a variety of therapeutic areas including anti-infectives, wet macular degeneration, glaucoma, and ocular inflammation. Highlights of this new research include:
The following schedule includes all Bausch + Lomb-supported poster presentations that will be featured during the meeting:
Pharmacology and Clinical Studies
546 - A0182. “NO-induced Regulation of Primary Human Trabecular Meshwork Cell Contractility by Latanoprostene Bunod.” Cavet, Megan E.; Vollmer, Thomas R.; Harrington, Karen; VanDerMeid, Karl; Richardson, Mary. [Sunday, May 4, 1:30 – 3:15 p.m., Exhibit/Poster Hall, Pharmacology and Clinical Studies].
548 - A0184. “Efficacy of Latanoprostene Bunod Ophthalmic Solution, 0.024%, in Lowering Intraocular Pressure Over 24-Hours in Normal Japanese Subjects (KRONUS).” Araie, Makoto; Ong, Tuyen; Scassellati-Sforzolini, Baldo; Ngumah, Quintus; Vittitow, Jason L.; Weinreb, Robert N. [Sunday, May 4, 1:30 – 3:15 p.m., Exhibit/Poster Hall, Pharmacology and Clinical Studies].
1489 - C0128. “Antibacterial Susceptibility of Coagulase Negative Staph Before and After Prophylactic Use of Besifloxacin and Moxifloxacin.” Bucci, Frank A.; Sanfilippo, Christine M.; DeCory, Heleen H.; Amico, Loretta; Evans, Ruth E.; Comstock, Timothy L. [Monday, May 5, 8:30 – 10:15 a.m., Exhibit/Poster Hall, Ocular Surface Health and Disease].
650 - C0060. “Circulating Omega-3 Fatty Acids and Neovascular Age-related Macular Degeneration.” Merle, Benedicte; Benlian, Pascale; Puche, Nathalie; Bassols, Ana; DelCourt, Cecile; Souied, Eric H. [Sunday, May 4, 1:30 – 3:15 p.m., Exhibit/Poster Hall, Retinal diseases in the aged eye].
“SIG – Organizer.” Emmanuel S. Buys; W Daniel Stamer; Emmanuel S. Buys; W Daniel Stamer; Louis R. Pasquale; Paul L.Kaufman; Jason L. Vittitow. [Sunday, May 4, 1:30 – 3 p.m., S 310A-D, New insights into the role of nitric oxide signaling in glaucoma - SIG].
“Development of a Nitric Oxide-Donating Prostaglandin for the Treatment of Glaucoma.” Jason L. Vittitow. [Sunday, May 4, 1:30 – 3 p.m., S 310A-D, New insights into the role of nitric oxide signaling in glaucoma - SIG].
6297 - B0248. “In vitro Antibiotic Susceptibility Profile of Ocular Pathogens - Results from the First ARMOR Canada Surveillance Study.” Blondeau, Joseph M.; Sanfilippo, Christine M.; Morris, Timothy W.; Deane, Jennifer; Sahm, Daniel F. [Tuesday, May 6, 8:30 – 10:15 a.m., Exhibit/Poster Hall SA, Clinical and Translational Studies in Ocular Infection and Immunity].
Dry Eye Disease
3690 - A0204. “Objective Evaluation of Ocular Surface Lubricants in Dry Eye Patients using Thermal Imaging.” Ranjini Kottaiyan; Holly B. Hindman; Geunyoung Yoon; Stephen Davio; James Zavislan; James Aquavella. [Tuesday, May 6, 3:45 – 5:30 p.m., Exhibit/Poster, Hall SA, Dry Eye Disease #2].
5790 - B0215. “Besifloxacin Ophthalmic Suspension, 0.6% Compared with Gatifloxacin Ophthalmic Solution, 0.3% for the Treatment of Bacterial Conjunctivitis in Neonatal Patients.” Ong, Tuyen; Allaire, Catherine; Morris, Timothy W.; Sforzolini, Baldo [Thursday, May 8, 8:30 – 10:15 a.m., Exhibit/Poster Hall SA, Antimicrobials].
Corneal Infection and Inflammation
6281 - B0200. “Antibiotic Resistance Profile of Ocular Pathogens – An Update from the 2013 US ARMOR Surveillance Study.” Sanfilippo, Christine M; Morris, Timothy W.; Deane, Jennifer; Draghi, Deborah C.; Sahm, Daniel F. [Thursday, May 8, Noon – 1:45 p.m., Exhibit/Poster Hall SA, Corneal Infection and Inflammation].
6297 - B0248. “Anti-inflammatory Effects of the Glucocorticoid Loteprednol Etabonate in Human Ocular and Inflammatory Cells.” Vollmer, Thomas R.; Cavet, Megan E.; Harrington, Karen L.; Volhejn, Stepan M.; Richardson, Mary. [Thursday, May 8, Noon – 1:45 p.m., Exhibit/Poster Hall SA, Cornea/ocular surface / ocular inflammation: pharmacology].
864. “Surface Characterization of the Interaction Between Peroxide Neutralizing Disks and Platinum
Modulating Compounds.” Kimberly A. Millard; Suzanne F. Groemminger; Andrew Hoteling; Daniel Hook; Katarzyna Wygladacz. [Sunday, May 4, 4:30 – 4:45 p.m., S 331A-D, Contact Lens].
4636 - A0261. “Predicted logMAR Image Resolution During Dehydration for Silicone Hydrogel Contact Lenses.” Paul Ludington; Kristen Hovinga; Mohinder Merchea. [Wednesday, May 7, 11 a.m. – 12:45 p.m., Exhibit/Poster Hall SA, Contact Lens].
4640 - A0265. “Surface and Bulk Properties of a Novel Inherently Wettable Silicone Hydrogel Material.” Katarzyna A. Wygladacz; Anthony Taddei; Daniel Hook. [Wednesday, May 7, 11 a.m. – 12:45 p.m., Exhibit/Poster Hall SA, Contact Lens].
4645 - A0270. “Influence of Buffering Systems on Acanthamoeba Encystment Following Prolonged Storage with Experimental Formulations and a Novel Hydrogen Peroxide-based Disinfecting Solution.” Shawn C. Lynch; Christopher Kovacs; Kimberly A. Millard; Suzanne F. Groemminger; Timothy W. Morris. [Wednesday, May 7, 11 a.m. – 12:45 p.m., Exhibit/Poster Hall SA, Contact Lens].
4648 - A0273. “Optimizing Physical Properties of a Silicone Hydrogel Material with Dual Phase Polymerization Processing.” Andrew Hoteling; Daniel Hook; Ivan Nunez; Joseph McGee; Joseph Hoff. [Wednesday, May 7, 11 a.m. – 12:45 p.m., Exhibit/Poster Hall SA, Contact Lens].
4650 - A0275. “Novel Ethylenically Unsaturated Polycarbosiloxane Monomers for Next Generation Silicone Hydrogel Contact Lenses.” Alok K. Awasthi. [Wednesday, May 7, 11 a.m. – 12:45 p.m., Exhibit/Poster Hall SA, Contact Lens].
4654 - A0279. "Comparing the Static and Kinetic Friction of Unworn and Worn Silicone Hydrogel Contact Lenses.” Daniel Hook; Sandra Taft; Robert Steffen; Mohinder M. Merchea. [Wednesday, May 7, 11 a.m. – 12:45 p.m., Exhibit/Poster Hall SA, Contact Lens].
6046 - A0123. “Biocidal Efficacy of Hydrogen Peroxide Solutions against Clinical Isolates of Fungal
Pathogens.” Brien C. David; Deborah McGrath; Denise Callahan; Juliann Mason; Julie Bair; Tiffany Hilfiker; Patricia A.Walsh. [Thursday, May 8, Noon – 1:45 p.m., Exhibit/Poster Hall SA, Contact Lens].
6052 - A0129. “Simultaneous Determination of the Rate of Disinfection and Peroxide Neutralization of a Novel Hydrogen Peroxide Disinfecting System.” Deborah McGrath; Kimberly A. Millard; Damien Cordero; Timothy W. Morris. [Thursday, May 8, Noon – 1:45 p.m., Exhibit/Poster Hall SA, Contact Lens].
6063 - A0140. “Comparative Surface Smoothness Durability of a Novel Silicone Hydrogel Material.” Mohinder M. Merchea; Katarzyna A. Wygladacz; Daniel Hook. [Thursday, May 8, Noon – 1:45 p.m., Exhibit/Poster Hall SA, Contact Lens].
6067 - A0144. “Atomic Force Microscopy and Coefficient of Friction Analysis of Unworn and Worn Soft
Contact Lenses.” Jeffery Schafer; Robert Steffen; Katarzyna A. Wygladacz; Charles Lusignan; Daniel Hook; Kristin Simoncelli. [Thursday, May 8, Noon – 1:45 p.m., Exhibit/Poster Hall SA, Contact Lens].
Bausch + Lomb is also sponsoring an oral presentation that will be included in the glaucoma pharmacology and clinical studies section as follows:
Glaucoma Pharmacology and Clinical Studies
3549. “Efficacy of Latanoprostene Bunod Ophthalmic Solution 0.024% Compared with Timolol Maleate Ophthalmic Solution 0.5% in Lowering IOP over 24 hours in Subjects With Open Angle Glaucoma or Ocular Hypertension (CONSTELLATION).” Liu, John H.; Vittitow, Jason L.; Ngumah, Quintus; Weinreb, Robert N. [Tuesday, May 6, 3:45 – 5:30 p.m., Exhibit/Poster Hall SA, Glaucoma Pharmacology and Clinical Studies].
Important Risk Information about LOTEMAX Gel
LOTEMAX Gel Indication
LOTEMAX® GEL is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery.
Warnings and Precautions
Please see LOTEMAX Gel full prescribing information here(155.2 KB, PDF).
BESIVANCE® (besifloxacin ophthalmic suspension) 0.6 percent is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Aerococcus viridans*, CDC coryneform group G, Corynebacterium pseudodiphtheriticum*, Corynebacterium striatum*, Haemophilus influenzae, Moraxella catarrhalis*, Moraxella lacunata*, Pseudomonas aeruginosa*, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus hominis*, Staphylococcus lugdunensis*, Staphylococcus warneri*, Streptococcus mitis group, Streptococcus oralis, Streptococcus pneumoniae, and Streptococcus salivarius.
*Efficacy for this organism was studied in fewer than 10 infections.
Important Risk Information about BESIVANCE
Please see BESIVANCE full prescribing information here(214.8 KB, PDF).
About Bausch + Lomb
Bausch + Lomb, a Valeant Pharmaceuticals International, Inc. company, is a leading global eye health organization that is solely focused on protecting, enhancing, and restoring people’s eyesight. Our core businesses include ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. We develop, manufacture and market one of the most comprehensive product portfolios in our industry with products available in more than 100 countries.
Bausch + Lomb is a trademark of Bausch & Lomb Incorporated or its affiliates.
All other brand/product names are trademarks of their respective owners.
© Bausch & Lomb Incorporated
# # #
News Media Contacts
BioComm Network on behalf of Bausch + Lomb
The website you are about to visit is not affiliated with Bausch + Lomb Incorporated. Bausch + Lomb is not responsible for the content, format, maintenance, or policies of the website you are about to enter and does not monitor non-affiliated websites for accuracy. Links to non-affiliated websites are provided as a convenience; they do not constitute an endorsement or support of any programs, products, or services associated with the website.